Skip to content

Our Product

AcuCort’s first product is approved in Sweden under the brand name ISICORT® and in Denmark and Norway under the name Zeqmelit. The drug is approved for the treatment of acute and severe allergic reactions, croup in children, nausea and vomiting during chemotherapy and for patients with COVID-19 with breathing difficulties and need for oxygen therapy.

The goal is to commercialize ISICORT®/Zeqmelit globally, that is, in the EU, the US and selected key markets. The company’s strategy is to attract partners with regional or global market presence as well as expertise and resources to quickly launch after regulatory approval. Dialogues with potential partners in prioritized markets are ongoing.